KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to -$288.1 million.

  • Vertex Pharmaceuticals' Cash from Investing Activities rose 6494.71% to -$288.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$945.4 million, marking a year-over-year increase of 7492.31%. This contributed to the annual value of -$945.4 million for FY2025, which is 7492.31% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Cash from Investing Activities stood at -$288.1 million, which was up 6494.71% from -$117.0 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash from Investing Activities peaked at $175.6 million during Q4 2022, and registered a low of -$2.1 billion during Q1 2024.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$211.0 million (2021), whereas its average is -$426.0 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Cash from Investing Activities surged by 23104.48% in 2022, and later tumbled by 349529.41% in 2023.
  • Vertex Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$134.0 million in 2021, then skyrocketed by 231.04% to $175.6 million in 2022, then tumbled by 604.84% to -$886.5 million in 2023, then increased by 7.29% to -$821.9 million in 2024, then surged by 64.95% to -$288.1 million in 2025.
  • Its Cash from Investing Activities stands at -$288.1 million for Q4 2025, versus -$117.0 million for Q3 2025 and -$484.5 million for Q2 2025.